Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP)

Author's Avatar
Jul 19, 2019
Article's Main Image

DOPTELET Has Differentiated Profile as The Only Oral Thrombopoietin Receptor Agonist (TPO-RA) Approved for Treatment of ITP Without Food Type Restrictions